Drug General Information
Drug ID	D09GPB
Former ID	DCL000461
Drug Name	AZD2066
Drug Type	Small molecular drug
Indication	Major depressive disorder; GERD; Chronic neuropathic pain [ICD9: 296.2, 296.3, 338, 356.0, 356.8, 530,780; ICD10:F32, F33, G64, G90.0, K21, R52, G89]		Discontinued in Phase 2	[548676]
Therapeutic Class	Analgesics
Company	AstraZeneca
Structure		Download 2D MOL 3D MOL
Formula	C19H16ClN5O2
PubChem Compound ID	16041426
Target and Pathway
Target(s)	Metabotropic glutamate receptor 5	Target Info	Antagonist	[550288]
KEGG Pathway	Calcium signaling pathway
	Neuroactive ligand-receptor interaction
	Gap junction
	Long-term potentiation
	Retrograde endocannabinoid signaling
	Glutamatergic synapse
	Huntington's disease
PANTHER Pathway	Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
	Metabotropic glutamate receptor group III pathway
	Metabotropic glutamate receptor group I pathway
	Endogenous cannabinoid signaling
Reactome	G alpha (q) signalling events
	Class C/3 (Metabotropic glutamate/pheromone receptors)
WikiPathways	Hypothetical Network for Drug Addiction
	GPCRs, Class C Metabotropic glutamate, pheromone
	Gastrin-CREB signalling pathway via PKC and MAPK
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 548676	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027605)
Ref 550288	Clinical pipeline report, company report or official report of AstraZeneca (2009).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.